Media headlines about Myovant Sciences (NASDAQ:MYOV) have been trending somewhat negative on Saturday, Accern reports. Accern ranks the sentiment of press coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Myovant Sciences earned a news impact score of -0.11 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.7903558434925 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of Myovant Sciences (MYOV) traded up 2.63% on Friday, reaching $11.70. 13,694 shares of the company’s stock traded hands. Myovant Sciences has a 52-week low of $10.14 and a 52-week high of $15.50. The stock’s market cap is $705.28 million. The firm’s 50-day moving average is $11.59 and its 200-day moving average is $11.84.
Separately, Zacks Investment Research downgraded shares of Myovant Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, May 3rd. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $18.20.
ILLEGAL ACTIVITY WARNING: “Somewhat Critical Press Coverage Somewhat Unlikely to Affect Myovant Sciences (MYOV) Stock Price” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this story on another publication, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this story can be viewed at https://stocknewstimes.com/2017/07/29/somewhat-negative-media-coverage-somewhat-unlikely-to-affect-myovant-sciences-myov-share-price-updated.html.
Myovant Sciences Company Profile
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland.
Receive News & Ratings for Myovant Sciences Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences Ltd and related companies with MarketBeat.com's FREE daily email newsletter.
